Detection of \textit{parC} gene mutations associated with quinolone resistance in \textit{Mycoplasma genitalium}: evaluation of a multiplex real-time PCR assay

Kaveesha Bodiyabadu\textsuperscript{1,2,3}, Jennifer Danielewski\textsuperscript{2,3}, Suzanne M. Garland\textsuperscript{2,3,4}, Dorothy A. Machalek\textsuperscript{2,5}, Catriona S. Bradshaw\textsuperscript{6,7}, Joshua Birnie\textsuperscript{3}, Samantha Ebeyan\textsuperscript{1}, Marie Lundgren\textsuperscript{1} and Gerald Murray\textsuperscript{2,3,4,}\textsuperscript{*}

\textbf{INTRODUCTION}

\textit{Mycoplasma genitalium} is a sexually transmitted pathogen associated with a number of syndromes in males and females \cite{1, 2}. Treatment of infection is complicated by increasing levels of resistance to the recommended first line treatment, the macrolide azithromycin, and second line treatment, the fluoroquinolone moxifloxacin \cite{3}.

Single nucleotide polymorphisms (SNPs) that confer resistance to azithromycin are well characterised, and tests reporting detection of \textit{M. genitalium} and markers for resistance \cite{4} have led to improved therapeutic outcomes through resistance-guided therapy \cite{5, 6}. In contrast, the contribution of specific SNPs to fluoroquinolone-resistance remains unclear; associations have been drawn with SNPs in the \textit{parC} gene resulting in changes at amino acid position S83 (A247C/S83R, G248T/S83I, G248A/S83N) and D87 (G259A/D87N, G259T/D87Y, G259C/D87H).

\textbf{Abstract}

\textbf{Introduction.} Increasing levels of antibiotic resistance are complicating treatment for the sexually transmitted pathogen \textit{Mycoplasma genitalium}. Resistance to fluoroquinolones is associated with mutations in the \textit{parC} gene. Although the precise mutations conferring resistance are not fully understood, the single nucleotide polymorphism (SNP) G248T/S83I is most implicated.

\textbf{Aim.} To evaluate the performance of the MG+\textit{parC}(beta2) assay (SpeeDx, Australia), which detects single nucleotide polymorphisms (SNPs) in the \textit{parC} gene at amino acid position S83 (A247C/S83R, G248T/S83I, G248A/S83N) and D87 (G259A/D87N, G259T/D87Y, G259C/D87H).

\textbf{Methods.} Clinical samples were analysed by MG+\textit{parC}(beta2) assay and results compared to Sanger sequencing. Sensitivity, specificity, and predictive value for treatment failure were calculated.

\textbf{Results.} From analysis of 205 samples, the MG+\textit{parC}(beta2) assay performed with a high sensitivity 98.2\% (95\% CI:90.3–100) and specificity 99.3\% (95\% CI:96.3–100) for \textit{parC} SNP detection with a kappa of 0.97 (95\% CI:0.94–1.00). The predictive value of G248T/S83I detection (the most common SNP, prevalence of 13\% in the study population) was analysed with respect to treatment failure (patients received sequential doxycycline-moxifloxacin). The positive-predictive-value for moxifloxacin failure after detection of S83I was only 44\% (95\% CI:24.4–65.1), while negative-predictive-value was high at 96.9\% (95\% CI:92.7–99.0), suggesting that other SNPs are contributing to resistance.

\textbf{Conclusion.} MG+\textit{parC}(beta2) performed with high concordance compared to Sanger sequencing. Such qPCR assays can assist in understanding causes of treatment failure, inform the development of diagnostic assays, and can be applied to surveillance of mutations in populations. Due to an incomplete understanding of the basis for fluoroquinolone resistance, such tests do not appear to be ready for clinical application.
S83R, G248T/S83I) [7–9] and D87 (G259A/D87N, G259T/D87Y) [10]. Of these, G248T/S83I is the most strongly implicated in resistance, however, approximately 45% of patients with infections exhibiting this SNP experience cure with fluoroquinolone treatment [7, 9]. Additional SNPs, not clearly linked with treatment failure, have also been described. These include G259C/D87H [11] and G248A/S83N (more common in Europe) [12–14].

Research tools that detect SNPs can help to develop an understanding of causes of treatment failure and inform the development of diagnostic assays. Quantitative PCR-based assays are generally quicker, more convenient, and cheaper than Sanger sequencing. We previously evaluated the test MG+\parC(beta) (manufactured by SpeeDx Pty Ltd.), master mix (15 µl) was mixed with sample extract (5 µl) and analysed on the LightCycler 480 II (Roche Diagnostics) with the following cycling conditions: one cycle of polymerase activation (95 °C, 2 min, ramp 4.4 °C s⁻¹), 10 cycles of touchdown cycling (0.5 °C per cycle, 61–56.5 °C, 30s per cycle, ramp 2.2 °C s⁻¹) followed by 40 cycles of quantification cycling/data acquisition (95 °C, 5s, ramp 4.4 °C s⁻¹; 52 °C 40s 2.2 °C s⁻¹), with a final step of cooling (40 °C, 30s, 2.2 °C s⁻¹). Data acquisition was performed using filter combinations indicated (Table 1). Results for the MG+\parC(beta2) assay were compared to the gold standard of Sanger sequencing [9] (Fig. 1).

RESULTS AND DISCUSSION
Performance of the MG+\parC(beta2) assay compared to Sanger sequencing
A total of 205 out of 242 (84.7%) \textit{M. genitalium} samples were successfully analysed by both methods (187 of these were pre-treatment samples). Sanger sequencing identified mutations targeted by the MG+\parC(beta2) assay in 55 samples (n=40 G248T/S83I, n=13 G259A/D87N, n=2 G248A/S83N). The MG+\parC(beta2) assay performed with a high sensitivity 98.2% (95% CI:90.3–100) and specificity 99.3% (95% CI:96.3–100) for \parC SNP detection with a kappa of 0.97 (95% CI: 0.94–1.00) (Table 2).

Analysis of results in the context of treatment outcomes
The treatment outcomes for the patients in this study group are known, with 92% of patients cured by sequential doxycycline-moxifloxacin treatment, and 8% failing treatment [6]. This allowed calculation of the positive predictive value of the assay for treatment failure. The most common SNP in the study

| Table 1. Summary of the MG+\parC(beta2) assay |
|---------------------------------------------|
| Reagent mix | Target* | Amino acid change | Fluorophore† | Detection filters (nm) |
| Mix 1 | G248T | S83I | Texas Red | 618–660 |
| | A247C | S83R | Texas Red | 618–660 |
| | G248A | S83N | JOE | 533–580 |
| | MgPa | NA | FAM | 465–510 |
| | Internal control | NA | Cy5 | 533–610 |
| Mix 2 | G259T | D87Y | Texas Red | 618–660 |
| | G259A | D87N | Texas Red | 618–660 |
| | G259C | D87H | Texas Red | 618–660 |
| | MgPa | NA | FAM | 465–510 |

*The assay target was either a single nucleotide polymorphism affecting the QRDR of \parC, internal control, or the MgPa gene (for \textit{M. genitalium} detection). Reference genome for indicated changes, \textit{M. genitalium} G37, GenBank accession number NC_000908. Numbering refers to \textit{M. genitalium} gene numbering.
†Texas Red, sulforhodamine 101 acid chloride; JOE, 6-carboxy-4′,5′-dichloro-2′,7′-dimethoxyfluorescein; FAM, 6-carboxyfluorescein dye.

METHODS
Samples used for this study
\textit{M. genitalium}-positive samples (n=242), were previously collected from patients undergoing sequential doxycycline-moxifloxacin treatment for macrolide-resistant \textit{M. genitalium} [6]. The samples included 223 pre-treatment samples (a diagnostic sample taken prior to any antibiotic therapy) and 19 test of cure samples. Sample types included 166 urine, and 45 anal, 14 cervical, 14 vaginal/high vaginal, and two urethral swabs, plus one swab of unknown site.

Analysis methodology
Samples were extracted on the MagNA Pure 96 instrument using the DNA and Viral NA Small Volume Kit (Roche) with 100 µl elution volume [9]. To perform the MG+\parC(beta) assay (manufactured by SpeeDx Pty Ltd.), master mix (15 µl) was mixed with sample extract (5 µl) and analysed on the LightCycler 480 II (Roche Diagnostics) with the following cycling conditions: one cycle of polymerase activation (95 °C, 2 min, ramp 4.4 °C s⁻¹), 10 cycles of touchdown cycling (0.5 °C per cycle, 61–56.5 °C, 30s per cycle, ramp 2.2 °C s⁻¹) followed by 40 cycles of quantification cycling/data acquisition (95 °C, 5s, ramp 4.4 °C s⁻¹; 52 °C 40s 2.2 °C s⁻¹), with a final step of cooling (40 °C, 30s, 2.2 °C s⁻¹). Data acquisition was performed using filter combinations indicated (Table 1). Results for the MG+\parC(beta2) assay were compared to the gold standard of Sanger sequencing [9] (Fig. 1).
population was G248T/S83I, present at 13% of pre-treatment samples. The positive-predictive-value of the detection of S83I for treatment failure was determined by focusing on the assay channel reporting S83I/S83R (Table 1; note that there were no S83R SNPs in the study). From 187 pre-treatment samples the positive-predictive-value of S83I detection for moxifloxacin failure (which followed a week of doxycycline) was only 44% (95% CI: 24.4–65.1), while negative-predictive-value was high at 96.9% (95% CI: 92.7–99.0). Other SNPs were rare in the study population. G259A/D87N was the next most prevalent, present in 6% of successfully analysed baseline samples. However, this mutation was equally represented in cures and failures.

The parC SNP G248T/S83I is the most strongly implicated mutation in M. genitalium fluoroquinolone resistance [7–9].
The results of this study indicate that detection of S83I has a low predictive value for moxifloxacin failure (particularly when used following doxycycline) and suggests that fluoroquinolone resistance may have a more complex basis than macrolide resistance, as outlined in the Introduction. Notably, in this study the pre-treatment of patients with doxycycline prior to moxifloxacin may have impacted cure, so the findings here do not necessarily translate to the situation where preceding doxycycline is not used. However, it is also important to note that quinolone resistance assays are likely to be used in the context of sequential doxycycline-moxifloxacin treatment as doxycycline is recommended within sequential treatment for M. genitalium in Australia and the UK [16, 17], and doxycycline is recommended for initial treatment of NGU (Europe, UK, Australia) [16–18], and as one of two recommended regimens for NGU in the USA [19].

As mentioned above, resistance to fluoroquinolones appears to be more complex than the situation for macrolides. There are other SNPs that are not captured by current parC assays that may contribute to resistance. These include SNPs affecting amino acids M95 and D99 in gyrA, which may have an additive effect when combined with parC SNPs [9]. Undefined variations elsewhere in the genome may also contribute. The results of this study demonstrate current limitations in using parC-based assays to triage patients away from moxifloxacin treatment while we still don’t have a clear understanding of mechanisms of resistance [20]. This is particularly important in an environment where there are limited alternative treatments for M. genitalium.

This MG+parC(beta2) assay was used in an earlier study using a smaller study group [21]. Sanger sequencing wasn’t used to confirm mutations, which were few in number (n=7), and treatment data were only available for three patients, so it is difficult to draw comparisons with the current study.

### Table 2. Comparison of single nucleotide polymorphism (SNP) detection for the MG+parC(beta2) assay compared to Sanger sequencing*

| Sanger sequencing | Mutant | Wild-type | Total |
|-------------------|--------|-----------|-------|
| MG+parC(beta2)     |        |           |       |
| Mutant            | 541    | 14        | 55    |
| Wild-type         | 19     | 149       | 150   |
| Total             | 55     | 150       |       |

*Both baseline and test of cure samples are included.
†The 40 G248T/S83I SNPs (all detected by assay), 13 G259A/D87N mutations (12/13 detected by assay), 2 G248A/S83N mutations (all detected by assay), SNPs in the parC quinolone-resistance-determinant region not targeted by this assay include A260G/D87G, A247T/S83C.
‡Determined to be WT by sequencing, but G259A/D87N by MG+parC(beta2).
§Determined to be G259A/D87N by sequencing.

### Study limitations

Lower load samples are less likely to yield a successful sequencing result, so it is possible that they were not included in the analysis. Additionally, results for Australian samples may not be generalizable to other locations.

### CONCLUSION

MG+parC(beta2) showed very high specificity and sensitivity for detection of SNPs potentially associated with fluoroquinolone resistance. Such quantitative PCR-based assays are generally quicker and cheaper than Sanger sequencing, making this assay a useful tool for detecting parC mutations to investigate treatment failure and for the surveillance of mutations in populations.

### Funding information

This work was supported by Victorian Medical Research Acceleration Fund, Department of Health, State Government of Victoria. The MG+parC(beta2) kits were supplied by SpeeDx.

### Conflicts of interest

The authors acknowledge the support of SpeeDx in providing testing kits for this study. K. B., S. E. and M. L., are employed by SpeeDx.

### Ethical statement

Ethical approval was obtained from the Royal Women’s Hospital Research and Ethics Committees (AQA17-43) and due to its low risk nature, was considered exempt from written consent.

### References

1. Horner PJ, Martin DH. Mycoplasma genitalium infection in men. J Infect Dis 2017;216:S396–S405.
2. Lis R, Rowhani-Rahbar A, Manhart LE. Mycoplasma genitalium infection and female reproductive tract disease: a meta-analysis. Clin Infect Dis 2015;61:418–426.
3. Machalek DA, Tao Y, Shilling H, Jensen JS, Unemo M. Prevalence of macrolide and fluoroquinolone resistance-associated mutations in Mycoplasma genitalium: a systematic review and meta-analysis. Lancet Infect Dis 2020;Accepted for publication 02 July 2020.
4. Tabrizi SN, Su J, Bradshaw CS, Fairley CK, Walker S et al. Prospective evaluation of ResistancePlus Mg, a new multiplex quantitative PCR assay for detection of Mycoplasma genitalium and macrolide resistance. J Clin Microbiol 2017;55:1915–1919.
5. Read TRH, Murray GL, Danielewski JA, Fairley CK, Doyle M et al. Symptoms, sites, and significance of Mycoplasma genitalium in men who have sex with men. Emerg Infect Dis 2019;25:719–727.
6. Durukan D, Read TRH, Murray G, Doyle M, Chow EPF et al. Resistance-guided antimicrobial therapy using doxycycline-moxifloxacin and doxycycline-2.5g azithromycin for the treatment of Mycoplasma genitalium infection: efficacy and tolerability. Clin Infect Dis 2020;71:1017–1024.
7. Murray GL, Bradshaw CS, Bissessor M, Danielewski J, Garland SM et al. Increasing macrolide and fluoroquinolone resistance in Mycoplasma genitalium. Emerg Infect Dis 2017;23:809–812.
8. Coulwdwell DL, Tagg KA, Jeffreys NJ, Gilbert GL. Failure of moxifloxacin treatment in Mycoplasma genitalium infections due to macrolide and fluoroquinolone resistance. Int J STD AIDS 2013;24:822–828.
9. Murray GL, Bodiyabadu K, Danielewski J, Garland SM, Machalek DA. Moxifloxacin and sitafloxacin treatment failure in Mycoplasma genitalium infection: association with parC Mutation G248T (S83I) and concurrent gyrA mutations. J Infect Dis 2019;221:1017–1024.
10. Deguchi T, Maeda S, Tamaki M, Yoshida T, Ishiko H et al. Analysis of the gyrA and parC genes of Mycoplasma genitalium detected...
in first-pass urine of men with non-gonococcal urethritis before and after fluoroquinolone treatment. *J Antimicrob Chemother* 2001;48:742–744.

11. Tagg KA, Jeffreys NJ, Couldwell DL, Donald JA, Gilbert GL. Fluoroquinolone and macrolide resistance-associated mutations in *Mycoplasma genitalium*. *J Clin Microbiol* 2013;51:2245–2249.

12. Shipitsyna E, Rumyantseva T, Golparian D, Khayrullina G, Lagos AC et al. Prevalence of macrolide and fluoroquinolone resistance-mediating mutations in *Mycoplasma genitalium* in five cities in Russia and Estonia. *PLoS One* 2017;12:e0175763.

13. Hadad R, Golparian D, Lagos AC, Ljungberg J, Nilsson P et al. Macrolide and fluoroquinolone resistance in *Mycoplasma genitalium* in two Swedish counties, 2011–2015. *APMIS* 2018;126:123–127.

14. Unemo M, Salado-Rasmussen K, Hansen M, Olsen AO, Falk M et al. Clinical and analytical evaluation of the new Aptima *Mycoplasma genitalium* assay, with data on *M. genitalium* prevalence and antimicrobial resistance in *M. genitalium* in Denmark, Norway and Sweden in 2016. *Clin Microbiol Infect* 2018;24:533–539.

15. Fernández-Huerta M, Bodiyabadu K, Esperalba J, Bradshaw CS, Serra-Pladevall J et al. Multicenter clinical evaluation of a novel multiplex real-time PCR (qPCR) assay for detection of fluoroquinolone resistance in *Mycoplasma genitalium*. *J Clin Microbiol* 2019;57:e00886–00819.

16. BASHH UK. Update to the 2015 BASHH UK national guideline on the management of non-gonococcal urethritis. https://www.bashh.org/guidelines [accessed 30th June 2020] 2018.

17. Australian STI Management Guidelines For Use in Primary Care. http://www.sti.guidelines.org.au/sexually-transmissible-infections/mycoplasma-genitalium [accessed 30th June 2020] 2018.

18. Horner PJ, Blee K, Falk L, van der Meijden W, Moi H. 2016 European guideline on the management of non-gonococcal urethritis. *Int J STD AIDS* 2016;27:928–937.

19. CDC. 2015 Sexually transmitted disease treatment guidelines. https://www.cdc.gov/std/tg2015/emerging.htm#myco [accessed 30th June 2020 2019]. 2015.

20. Manhart LE, Jensen JS. Quinolone resistance-associated mutations in *Mycoplasma genitalium*: not ready for prime time. *Sex Transm Dis* 2020;47:199–201.

21. Conway RJH, Cook S, Malone C, Bone S, Hassan-Ibrahim MO et al. Clearance of *Mycoplasma genitalium* infection with moxifloxacin in the presence of quinolone resistance-associated mutations. *Sex Transm Dis* 2020;47:197–198.